The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC).
The MHRA previously approved retifanlimab on July 6, 2026 for the treatment of adults with advanced Merkel cell carcinoma (MCC) - a rare, aggressive type of skin cancer.
Retifanlimab is used in combination with carboplatin and paclitaxel, which are chemotherapy medicines, and works by helping the body’s immune system recognise and attack cancer cells. It blocks a pathway that cancer cells can use to avoid being detected by the immune system, allowing immune cells to better identify and destroy them.
“This approval provides a new treatment option for adults whose cancer cannot be removed by surgery or has spread to other parts of the body or returned to the same area.
“As with all medicines, we will continue to closely monitor the safety and effectiveness of retifanlimab as it is used more widely.”
